CARDIOXYL PHARMACEUTICALS TO PRESENT DATA AT TWO CARDIOLOGY CONFERENCES
New Preclinical Data to be Presented at the 13th Annual Heart Failure Society of America and the American Heart Association
Hunt Valley, MD - September 10, 2009 - Cardioxyl Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular disease, today announced that the company will present preclinical data on Cardioxyl’s lead program, CXL-1020, at the 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) and the American Heart Association (AHA) Scientific Sessions. CXL-1020 is an intravenous agent under development for the treatment of Acute Decompensated Heart Failure (ADHF), and is currently being evaluated in a Phase I/IIa study in patients with stable heart failure.
Chris Kroeger, MD, President and Chief Executive Officer of Cardioxyl Pharmaceuticals, commented, “Cardioxyl’s lead candidate, CXL-1020, has a unique mechanism of action producing three key physiological effects in canine heart failure models; improved contractility, enhanced relaxation and reduced load. This unique constellation of effects suggests a highly valuable pharmacologic profile suitable for the treatment of ADHF. The Company has made significant progress in advancing CXL-1020 in the clinic, and we are excited to have the opportunity to share some of our preclinical research findings at these two prestigious scientific meetings.”
13th Annual Scientific Meeting of the Heart Failure Society of America
Poster 1:
| Who: | Mengjun Wang, MD, Itamar Ilsar, DVM, Alice Wang, MD, Michael S. Sabbah, BSc and Hani N. Sabbah, PhD, Henry Ford Health System, and Reza Mazhari, PhD, Cardioxyl Pharmaceuticals, Inc. | |
|---|---|---|
| Title: | “Acute Intravenous Infusion of CXL-1020, A Novel Nitroxyl (HNO) Donor, Improves Left Ventricular Systolic and Diastolic Function in Dogs With Advanced Heart Failure” | |
| When: | Monday, September 14 at 5:30 p.m. | |
| Where: | Exhibit Hall C and D, Hynes Convention Center, Boston, Massachusetts | |
| Website: | http://www.hfsa.org/annual_meeting.asp |
Poster 2:
| Who: | Samantapudi Daya, MD, Richard S Tunin, Johns Hopkins University, Reza Mazhari, PhD, David A Kass, MD, Cardioxyl Pharmaceuticals, Inc. |
|---|---|
| Title: | “Intravenous Infusion of Novel HNO Donor, CXL-1020, Improves Left Ventricular Contractile Function in Normal and Failing Dogs” |
| When: | Monday, September 14 at 5:30 p.m. |
| Where: | Exhibit Hall C and D, Hynes Convention Center, Boston, Massachusetts |
| Website: | http://www.hfsa.org/annual_meeting.asp |
American Heart Association Scientific Sessions
Oral Presentation:
| Who: | Mengjun Wang, Itamar Ilsar, Hani N Sabbah, Alice Jiang, Michael S Sabbah, Ramesh C Gupta, Henry Ford Hospital; T D Cowart, Reza Mazhari, Cardioxyl Pharmaceuticals, Inc. |
|---|---|
| Title: | “Acute Intravenous Infusion of CXL-1020, a Nitroxyl Donor, Improves Left Ventricular Function in Dogs With Advanced Heart Failure” |
| When: | Tuesday, November 17 at 2:00 p.m. |
| Where: | Exhibit Hall, Orange County Convention Center, Orlando, Florida |
| Website: | http://scientificsessions.americanheart.org/portal/scientificsessions/ss/program |
About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery
and development of new classes of safe and effective therapeutic agents for the treatment of
cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry,
biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO
platform has generated several preclinical and clinical candidates, including the company's lead
compound, CXL-1020, currently in clinical development for ADHF. Cardioxyl is a privately held
company financed by life science venture investors, including the Aurora Funds and New
Enterprise Associates.
# # #
